Time between onset of symptoms and start of the antiviral treatment,
mean ± SD (min–max)
|
5.1 ± 3.0 (0-21)
n=479
|
3.5 ± 2.2 (0-14)
n=266
|
<0.001
|
Patient treated within 5 days of symptoms, % (n) |
57.2 (274 /479) |
86.8 (231/266) |
<0.001 |
Patient treated within 3 days of symptoms, % (n) |
27.8 (133/479) |
53.4 (142/266) |
<0.001 |
Immunomodulators, % (n) |
56.3 (276) |
55.9 (152) |
>0.05 |
Tocilizumab |
14.9 (73) |
9.6 (26) |
0.04 |
Dexamethason |
49.6 (243) |
54.4 (148) |
>0.05 |
Baricitinib |
1.2 (6) |
3.3 (9) |
0.04 |
Antibiotics, % (n) |
34.1 (167) |
41.2 (112) |
0.05 |
Low molecular weight heparin in prophylactic dose, % (n) |
73.1 (358) |
73.5 (200) |
>0.05 |
Low molecular weight heparin in a therapeutic dose, % (n) |
16.9 (83) |
23.5 (64) |
0.03 |